Shots:
ViiV has reported the P-IIIb (CROWN) trial data assessing Cabenuva (cabotegravir + rilpivirine [CAB + RPV LA]) vs SoC oral antiretroviral therapy (ART) in adults & adolescents (n=326) with HIV-1 who had detectable virus when they entered the study
Cabenuva achieved superior viral suppression vs SoC at 6mos., meeting the 1EP & addressing an…
